Bryce Point Capital LLC Makes New $558,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bryce Point Capital LLC purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 783 shares of the biopharmaceutical company’s stock, valued at approximately $558,000.

A number of other hedge funds also recently bought and sold shares of the company. Huntington National Bank raised its holdings in Regeneron Pharmaceuticals by 51.9% in the fourth quarter. Huntington National Bank now owns 919 shares of the biopharmaceutical company’s stock worth $655,000 after buying an additional 314 shares during the last quarter. Kesler Norman & Wride LLC bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $316,000. Groupama Asset Managment increased its position in shares of Regeneron Pharmaceuticals by 12.7% during the fourth quarter. Groupama Asset Managment now owns 80,339 shares of the biopharmaceutical company’s stock valued at $56,445,000 after acquiring an additional 9,062 shares in the last quarter. Trexquant Investment LP raised its holdings in Regeneron Pharmaceuticals by 305.9% in the 4th quarter. Trexquant Investment LP now owns 56,625 shares of the biopharmaceutical company’s stock worth $40,336,000 after acquiring an additional 42,674 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Regeneron Pharmaceuticals by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock valued at $1,726,940,000 after acquiring an additional 155,369 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $625.60 on Thursday. The business has a 50-day moving average price of $680.43 and a 200-day moving average price of $786.93. The firm has a market cap of $68.39 billion, a price-to-earnings ratio of 16.34, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a twelve month low of $605.56 and a twelve month high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the firm posted $11.86 EPS. The company’s revenue was up 10.3% on a year-over-year basis. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.56%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on REGN shares. Bank of America restated an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their target price for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. Wells Fargo & Company dropped their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Citigroup lowered their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Finally, Piper Sandler cut their target price on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $966.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.